Overview

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nektar Therapeutics